Stoke Therapeutics, Inc. (NASDAQ:STOK) Receives Consensus Rating of “Moderate Buy” from Brokerages

Stoke Therapeutics, Inc. (NASDAQ:STOK) has earned a consensus rating of “Moderate Buy” from the eleven brokerages that are covering the stock, MarketBeat reports. Two equities research analysts have rated the stock with a hold rating, eight have given a buy rating and one has assigned a strong buy rating to the company. The average twelve-month price target among brokerages that have covered the stock in the last year is $39.1818.

A number of brokerages have issued reports on STOK. BTIG Research reissued a “buy” rating and issued a $39.00 price target on shares of Stoke Therapeutics in a report on Wednesday, November 5th. Loop Capital set a $35.00 target price on Stoke Therapeutics in a research note on Monday, January 5th. HC Wainwright boosted their price target on Stoke Therapeutics from $35.00 to $50.00 and gave the company a “buy” rating in a report on Monday, December 15th. Wedbush increased their price objective on Stoke Therapeutics from $32.00 to $36.00 and gave the stock an “outperform” rating in a report on Monday, January 12th. Finally, Chardan Capital boosted their target price on Stoke Therapeutics from $24.00 to $35.00 and gave the company a “buy” rating in a research note on Monday, January 5th.

Stoke Therapeutics Price Performance

Shares of Stoke Therapeutics stock opened at $31.91 on Tuesday. Stoke Therapeutics has a one year low of $5.35 and a one year high of $38.69. The business’s 50 day simple moving average is $31.61 and its two-hundred day simple moving average is $26.94. The stock has a market capitalization of $1.82 billion, a P/E ratio of 47.63 and a beta of 1.10.

Insider Buying and Selling at Stoke Therapeutics

In other Stoke Therapeutics news, General Counsel Jonathan Allan sold 8,785 shares of the company’s stock in a transaction on Friday, December 5th. The shares were sold at an average price of $31.29, for a total value of $274,882.65. Following the completion of the transaction, the general counsel directly owned 15,809 shares in the company, valued at approximately $494,663.61. This represents a 35.72% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Barry Ticho sold 3,662 shares of Stoke Therapeutics stock in a transaction dated Friday, December 5th. The shares were sold at an average price of $31.34, for a total transaction of $114,767.08. Following the sale, the insider directly owned 19,798 shares in the company, valued at $620,469.32. The trade was a 15.61% decrease in their position. The disclosure for this sale is available in the SEC filing. In the last ninety days, insiders have sold 58,302 shares of company stock valued at $1,826,430. 9.50% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently made changes to their positions in the company. Morgan Stanley grew its stake in Stoke Therapeutics by 0.3% in the fourth quarter. Morgan Stanley now owns 3,546,158 shares of the company’s stock worth $112,555,000 after purchasing an additional 9,108 shares during the period. Vanguard Group Inc. boosted its holdings in shares of Stoke Therapeutics by 7.4% during the 3rd quarter. Vanguard Group Inc. now owns 3,163,874 shares of the company’s stock valued at $74,351,000 after buying an additional 217,616 shares in the last quarter. State Street Corp grew its position in shares of Stoke Therapeutics by 75.2% in the 4th quarter. State Street Corp now owns 2,498,049 shares of the company’s stock worth $79,288,000 after buying an additional 1,072,176 shares during the period. Marshall Wace LLP increased its stake in shares of Stoke Therapeutics by 7.9% in the 2nd quarter. Marshall Wace LLP now owns 2,300,554 shares of the company’s stock worth $26,111,000 after acquiring an additional 168,771 shares in the last quarter. Finally, Goldman Sachs Group Inc. lifted its position in Stoke Therapeutics by 21.4% during the 1st quarter. Goldman Sachs Group Inc. now owns 1,662,039 shares of the company’s stock valued at $11,053,000 after acquiring an additional 293,072 shares during the period.

Stoke Therapeutics Company Profile

Stoke Therapeutics, headquartered in Bedford, Massachusetts, is a clinical-stage biopharmaceutical company focused on developing genetic medicines to upregulate protein production for the treatment of rare neuromuscular and neurological disorders. Founded in 2014, the company applies its proprietary Targeted Augmentation of Nuclear Gene Output (TANGO™) platform to design antisense oligonucleotides that selectively modulate RNA splicing and enhance expression of functional proteins.

The company’s lead program, STK-001, is an antisense oligonucleotide therapy designed to increase production of the sodium channel protein SCN1A and is currently in clinical development for Dravet syndrome, a severe childhood-onset epilepsy.